PHILADELPHIA PHARMACEUTICALS COMPANY |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.36 JOD | -1.45% |
|
0.00% | -4.90% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 11.85 | 11.7 | 10.72 | 10.28 | 10.42 | 10.72 |
| Enterprise Value (EV) 1 | 12.27 | 12.63 | 10.78 | 10.06 | 10.76 | 10.82 |
| P/E ratio | 11.7 x | 9.19 x | 75.7 x | 25 x | 14.9 x | 13.3 x |
| Yield | 3.16% | - | - | 4.38% | 4.32% | 4.9% |
| Capitalization / Revenue | 1.48 x | 1.28 x | 1.39 x | 1.56 x | 1.24 x | 1.28 x |
| EV / Revenue | 1.53 x | 1.39 x | 1.4 x | 1.52 x | 1.28 x | 1.29 x |
| EV / EBITDA | 7.91 x | 6.23 x | 14.4 x | 11.4 x | 8.83 x | 6.56 x |
| EV / FCF | 13.5 x | -24.8 x | 8.85 x | -61.6 x | -38.2 x | 20.8 x |
| FCF Yield | 7.39% | -4.04% | 11.3% | -1.62% | -2.62% | 4.8% |
| Price to Book | 1.1 x | 1 x | 0.94 x | 0.85 x | 0.84 x | 0.84 x |
| Nbr of stocks (in thousands) | 7,500 | 7,500 | 7,500 | 7,500 | 7,500 | 7,500 |
| Reference price 2 | 1.580 | 1.560 | 1.430 | 1.370 | 1.390 | 1.430 |
| Announcement Date | 3/17/19 | 3/9/20 | 6/7/21 | 3/3/22 | 3/16/23 | 2/11/24 |
1JOD in Million2JOD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 8 | 9.115 | 7.697 | 6.601 | 8.415 | 8.405 |
| EBITDA 1 | 1.551 | 2.026 | 0.7481 | 0.8793 | 1.218 | 1.649 |
| EBIT 1 | 1.277 | 1.692 | 0.4689 | 0.7192 | 1.098 | 1.355 |
| Operating Margin | 15.96% | 18.56% | 6.09% | 10.89% | 13.05% | 16.12% |
| Earnings before Tax (EBT) 1 | 1.069 | 1.43 | 0.1667 | 0.4939 | 0.8656 | 1.022 |
| Net income 1 | 1.009 | 1.274 | 0.1417 | 0.4102 | 0.7011 | 0.8072 |
| Net margin | 12.61% | 13.97% | 1.84% | 6.21% | 8.33% | 9.6% |
| EPS 2 | 0.1345 | 0.1698 | 0.0189 | 0.0547 | 0.0935 | 0.1076 |
| Free Cash Flow 1 | 0.9069 | -0.5099 | 1.217 | -0.1633 | -0.2815 | 0.5191 |
| FCF margin | 11.34% | -5.59% | 15.82% | -2.47% | -3.34% | 6.18% |
| FCF Conversion (EBITDA) | 58.49% | - | 162.71% | - | - | 31.48% |
| FCF Conversion (Net income) | 89.92% | - | 859.01% | - | - | 64.3% |
| Dividend per Share 2 | 0.0500 | - | - | 0.0600 | 0.0600 | 0.0700 |
| Announcement Date | 3/17/19 | 3/9/20 | 6/7/21 | 3/3/22 | 3/16/23 | 2/11/24 |
1JOD in Million2JOD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 0.42 | 0.93 | 0.05 | - | 0.33 | 0.09 |
| Net Cash position 1 | - | - | - | 0.21 | - | - |
| Leverage (Debt/EBITDA) | 0.2716 x | 0.4591 x | 0.0674 x | - | 0.2722 x | 0.0559 x |
| Free Cash Flow 1 | 0.91 | -0.51 | 1.22 | -0.16 | -0.28 | 0.52 |
| ROE (net income / shareholders' equity) | 9.63% | 11.3% | 1.23% | 3.48% | 5.72% | 6.42% |
| ROA (Net income/ Total Assets) | 5.91% | 7.1% | 1.89% | 2.99% | 4.44% | 5.32% |
| Assets 1 | 17.06 | 17.92 | 7.506 | 13.73 | 15.78 | 15.18 |
| Book Value Per Share 2 | 1.440 | 1.560 | 1.530 | 1.620 | 1.650 | 1.700 |
| Cash Flow per Share 2 | 0.1300 | 0.1600 | 0.2100 | 0.2200 | 0.2000 | 0.1900 |
| Capex 1 | 0.36 | 0.27 | 0.14 | 0.2 | 0.17 | 0.07 |
| Capex / Sales | 4.44% | 2.99% | 1.81% | 3.1% | 1.98% | 0.78% |
| Announcement Date | 3/17/19 | 3/9/20 | 6/7/21 | 3/3/22 | 3/16/23 | 2/11/24 |
1JOD in Million2JOD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -4.90% | 14.39M | |
| +22.35% | 44.12B | |
| +22.22% | 22.61B | |
| +17.89% | 15.11B | |
| +15.73% | 13.61B | |
| +57.91% | 13.34B | |
| -8.98% | 6.94B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +15.65% | 5.75B |
- Stock Market
- Equities
- PHIL Stock
- Financials Philadelphia Pharmaceuticals Company